September 2, 2019
by James O’Hanlon, Ph.D., Psychopharmacologist Most individuals with ASD suffer some degree of expressive and/or receptive language impairment. For the higher functioning it may only be a relative inability to comprehend the nuances of verbal or nonverbal...
April 1, 2019
by James O’Hanlon, Ph.D., Psychopharmacologist In 2005, neurologists at Johns Hopkins University published a postmortem study comparing 11 individuals with ASD and as controls, 11 typically developing individuals.1 Groups were matched with respect to age at death, 5...
September 3, 2018
by James O’Hanlon, Ph.D., Psychopharmacologist Most people know that alcohol and certain illicit drugs can promote feelings of hostility leading to impulsive aggression. Less well known is that many medicinal drugs from numerous therapeutic classes can do the same in...
April 2, 2018
by James O’Hanlon, Ph.D., Psychopharmacologist French medical scientists seem to have a knack for appreciating the properties of drugs, developed for other purposes, which make them suitable for treating neuropsychiatric disorders. The classic example was their...
September 4, 2017
by James O’Hanlon, Ph.D., Psychopharmacologist The rise of cannabidiol (CBD) to prominence began on August 11, 2013 with a CNN documentary about Charlotte Figi, a 5-year-old born with a rare, single-gene mutation that causes a devastating type of epilepsy – Dravet...
April 3, 2017
by James O’Hanlon, Ph.D., Psychopharmacologist Children with ASD are commonly hyperactive. This symptom is disruptive at home, limits learning in school and interferes with behavioral therapy. Of course many typically developing children with the diagnosis of...
